{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:16:06Z","timestamp":1787505366231,"version":"build-2736575974"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Obesity and metabolic syndrome (MetS) are commonly observed in patients with epilepsy (PWE). Obesity and MetS are not only affecting the physical fitness and quality of life of these patients, rather antiepileptic drugs (AEDs) compliance and seizure control have also been affected. The objective of this review is to search the published literature regarding the prevalence of obesity and MetS in PWE and their relation to the response to AEDs. A comprehensive search using PubMed, Cochrane Databases, and Google Scholar was performed. A supplementary citation search was also conducted by analyzing the reference lists of identified sources. The initial search revealed 364 articles of potential relevance. The studies were analyzed in detail to obtain clinical information relevant to the objectives of the review. Many observational, case control studies, randomized control trials and few review articles were included for critical appraisal and review writing. Epilepsy is associated with MetS and obesity in all age groups. AEDs and lack of exercise are the chief causes while metabolic disturbances such as adiponectin, mitochondrial dysfunction, valproic acid (VPA)-associated insulin resistance, leptin deficiency, and endocrine dysfunction are also addressable factors. Although the risk of drug-resistant epilepsy (DRE) is also higher among obese PWE, the interaction between, MetS, and its components with DRE remain to be fully investigated. Further research is required to elucidate their interplay. Appropriate and careful selection of AEDs without compromising therapeutic efficacy supplemented by lifestyle counseling for exercise and diet should be practiced to avoid weight gain and potential DRE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aam.aam_139_22","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T08:01:09Z","timestamp":1680508869000},"page":"136-144","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["Obesity and Metabolic Syndrome in Patients with Epilepsy, their Relation with Epilepsy Control"],"prefix":"10.4103","volume":"22","author":[{"given":"Saima","family":"Nazish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20240831","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2016.03.002","article-title":"Metabolic syndrome in young adults with epilepsy","volume":"37","author":"Nair","year":"2016","journal-title":"Seizure"},{"key":"R3-2-20240831","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(17)30084-4","article-title":"Neurological consequences of obesity","volume":"16","author":"O\u2019Brien","year":"2017","journal-title":"Lancet Neurol"},{"key":"R4-2-20240831","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2007.01402.x","article-title":"Weight issues for people with epilepsy \u2013 A review","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"R5-2-20240831","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/17512433.2015.991716","article-title":"Antiepileptic drugs influences on body weight in people with epilepsy","volume":"8","author":"Hamed","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R6-2-20240831","first-page":"849","article-title":"Comorbidity in adults with epilepsy. United States, 2010","volume":"62","author":"Kadima","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R7-2-20240831","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.yebeh.2018.05.041","article-title":"Correlation between clinical and cognitive aspects and nutritional indicators of elderly patients with new-onset epilepsy","volume":"85","author":"Tedrus","year":"2018","journal-title":"Epilepsy Behav"},{"key":"R8-2-20240831","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nn0311-277","article-title":"Lighting up the hypothalamus: Coordinated control of feeding behavior","volume":"14","author":"Williams","year":"2011","journal-title":"Nat Neurosci"},{"key":"R9-2-20240831","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1528-1167.2006.00478.x","article-title":"Physical activity in children\/teens with epilepsy compared with that in their siblings without epilepsy","volume":"47","author":"Wong","year":"2006","journal-title":"Epilepsia"},{"key":"R10-2-20240831","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1212\/01.WNL.0000048209.07526.86","article-title":"Fasting serum insulin and lipid levels in men with epilepsy","volume":"60","author":"Pylv\u00e4nen","year":"2003","journal-title":"Neurology"},{"key":"R11-2-20240831","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/ana.410390506","article-title":"Obesity and endocrine disorders in women taking valproate for epilepsy","volume":"39","author":"Isoj\u00e4rvi","year":"1996","journal-title":"Ann Neurol"},{"key":"R12-2-20240831","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.yebeh.2013.05.012","article-title":"Obesity in adults with epilepsy","volume":"28","author":"Janousek","year":"2013","journal-title":"Epilepsy Behav"},{"key":"R13-2-20240831","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1212\/WNL.0000000000002611","article-title":"Obesity and overweight as CAE comorbidities and differential drug response modifiers","volume":"86","author":"Arya","year":"2016","journal-title":"Neurology"},{"key":"R14-2-20240831","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/oby.2008.310","article-title":"The incidence rate of seizures in relation to BMI in UK adults","volume":"16","author":"Gao","year":"2008","journal-title":"Obesity (Silver Spring"},{"key":"R15-2-20240831","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1528-1167.2009.02477.x","article-title":"Health status and health-related behaviors in epilepsy compared to other chronic conditions \u2013 A national population-based study","volume":"51","author":"Hinnell","year":"2010","journal-title":"Epilepsia"},{"key":"R16-2-20240831","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.yebeh.2004.02.007","article-title":"Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: Behavioral risk factor surveillance system, 2002","volume":"5","author":"Kobau","year":"2004","journal-title":"Epilepsy Behav"},{"key":"R17-2-20240831","doi-asserted-by":"crossref","first-page":"106992","DOI":"10.1016\/j.yebeh.2020.106992","article-title":"Metabolic syndrome in people with epilepsy","volume":"106","author":"Vooturi","year":"2020","journal-title":"Epilepsy Behav"},{"key":"R18-2-20240831","first-page":"339","article-title":"prevelence and risk factors among patients with epielpsy attending a neuropsychiatric hospital in kigali, Rawanda","volume":"04","author":"FX","year":"2021","journal-title":"IJMRHS"},{"key":"R19-2-20240831","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.0b013e3181ab2b11","article-title":"Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy","volume":"73","author":"Daniels","year":"2009","journal-title":"Neurology"},{"key":"R20-2-20240831","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"R22-2-20240831","doi-asserted-by":"crossref","first-page":"143924","DOI":"10.1016\/j.gene.2019.06.014","article-title":"Involvement of MnSOD Ala16Val polymorphism in epilepsy: A relationship with seizure type, inflammation, and metabolic syndrome","volume":"711","author":"Kegler","year":"2019","journal-title":"Gene"},{"key":"R23-2-20240831","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ane.12313","article-title":"Insulin resistance in patients on valproic acid: Relation to adiponectin","volume":"131","author":"Aly","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"R24-2-20240831","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.seizure.2017.03.007","article-title":"Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study","volume":"48","author":"Sidhu","year":"2017","journal-title":"Seizure"},{"key":"R25-2-20240831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2007.04.001","article-title":"Leptin and insulin homeostasis in epilepsy: Relation to weight adverse conditions","volume":"75","author":"Hamed","year":"2007","journal-title":"Epilepsy Res"},{"key":"R26-2-20240831","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1080\/09638288.2019.1665113","article-title":"Physical activity correlates across the lifespan in people with epilepsy: A systematic review","volume":"43","author":"Vancampfort","year":"2021","journal-title":"Disabil Rehabil"},{"key":"R27-2-20240831","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy","volume":"11","author":"Ben-Menachem","year":"2003","journal-title":"Obes Res"},{"key":"R28-2-20240831","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1528-1157.2000.tb02175.x","article-title":"Topiramate as add-on therapy: Pooled analysis of randomized controlled trials in adults","volume":"41","author":"Reife","year":"2000","journal-title":"Epilepsia"},{"key":"R29-2-20240831","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ane.12373","article-title":"Effects of adjunctive zonisamide treatment on weight and body mass index in children with partial epilepsy","volume":"131","author":"Lagae","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"R30-2-20240831","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.283.6291.577","article-title":"Effects of sodium valproate in 100 children with special reference to weight","volume":"283","author":"Egger","year":"1981","journal-title":"Br Med J (Clin Res Ed"},{"key":"R31-2-20240831","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/WNL.56.2.172","article-title":"Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy","volume":"56","author":"Biton","year":"2001","journal-title":"Neurology"},{"key":"R32-2-20240831","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/08830738030180021701","article-title":"Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: Results from a post hoc analysis of a randomized, double-blind clinical trial","volume":"18","author":"Biton","year":"2003","journal-title":"J Child Neurol"},{"key":"R33-2-20240831","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0404.2003.00093.x","article-title":"Topiramate, carbamazepine and valproate monotherapy: Double-blind comparison in newly diagnosed epilepsy","volume":"107","author":"Privitera","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"R34-2-20240831","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ana.410430406","article-title":"Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy","volume":"43","author":"Isoj\u00e4rvi","year":"1998","journal-title":"Ann Neurol"},{"key":"R35-2-20240831","first-page":"193","article-title":"The prevalence of obesity and metabolic syndrome in paediatric patients with epilepsy treated in monotherapy with valproic acid","volume":"61","author":"Carmona-Vazquez","year":"2015","journal-title":"Rev Neurol"},{"key":"R36-2-20240831","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1528-1167.2009.02206.x","article-title":"The metabolic syndrome in overweight epileptic patients treated with valproic acid","volume":"51","author":"Verrotti","year":"2010","journal-title":"Epilepsia"},{"key":"R37-2-20240831","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.seizure.2012.06.001","article-title":"Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate","volume":"21","author":"Fang","year":"2012","journal-title":"Seizure"},{"key":"R38-2-20240831","doi-asserted-by":"crossref","first-page":"e103856","DOI":"10.1371\/journal.pone.0103856","article-title":"Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia","volume":"9","author":"Rakitin","year":"2014","journal-title":"PLoS One"},{"key":"R39-2-20240831","first-page":"e29","article-title":"Metabolic syndrome in children with epielpsy on valproate and phenytoin therapy: Across sectional study","volume":"10-15","author":"Sharma","year":"2013","journal-title":"Journal of Neurological sciences"},{"key":"R40-2-20240831","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.seizure.2018.06.003","article-title":"Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid","volume":"60","author":"Nisha","year":"2018","journal-title":"Seizure"},{"key":"R41-2-20240831","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/jpn.JPN_152_16","article-title":"Serum insulin and leptin levels in children with epilepsy on valproate-associated obesity","volume":"12","author":"Rehman","year":"2017","journal-title":"J Pediatr Neurosci"},{"key":"R42-2-20240831","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1046\/j.1528-1157.2002.31501.x","article-title":"Serum insulin and leptin levels in valproate associated obesity","volume":"43","author":"Pylvanen","year":"2002","journal-title":"Epilepsia"},{"key":"R43-2-20240831","first-page":"18","article-title":"Evaluation of serum ghrelin and neuropeptide Y levels in epileptic children under valproate treatment","volume":"26","author":"Guzel","year":"2009","journal-title":"Univ Tip Fak Derg"},{"key":"R44-2-20240831","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000077274","article-title":"Obesity and plasma concentrations of alpha-tocopherol and beta-carotene in epileptic girls treated with valproate","volume":"79","author":"Verrotti","year":"2004","journal-title":"Neuroendocrinology"},{"key":"R45-2-20240831","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.yebeh.2006.02.008","article-title":"Insulin-related metabolic changes during treatment with valproate in patients with epilepsy","volume":"8","author":"Pylv\u00e4nen","year":"2006","journal-title":"Epilepsy Behav"},{"key":"R46-2-20240831","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/1817-1745.165661","article-title":"Parameters of metabolic syndrome in Indian children with epilepsy on valproate or phenytoin monotherapy","volume":"10","author":"Dhir","year":"2015","journal-title":"J Pediatr Neurosci"},{"key":"R47-2-20240831","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.yebeh.2010.12.012","article-title":"Nonalcoholic fatty liver disease in adolescents receiving valproic acid","volume":"20","author":"Verrotti","year":"2011","journal-title":"Epilepsy Behav"},{"key":"R48-2-20240831","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eplepsyres.2009.04.004","article-title":"Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment","volume":"86","author":"Luef","year":"2009","journal-title":"Epilepsy Res"},{"key":"R49-2-20240831","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1528-1167.2008.01676.x","article-title":"Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: A cross-sectional study","volume":"49","author":"Sahota","year":"2008","journal-title":"Epilepsia"},{"key":"R50-2-20240831","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eplepsyres.2017.10.016","article-title":"Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either valproate or lamotrigine monotherapy: A prospective study","volume":"139","author":"Sidhu","year":"2018","journal-title":"Epilepsy Res"},{"key":"R51-2-20240831","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jnnp.57.6.682","article-title":"A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group","volume":"57","author":"Richens","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R52-2-20240831","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0920-1211(00)00125-X","article-title":"Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin","volume":"41","author":"Hogan","year":"2000","journal-title":"Epilepsy Res"},{"key":"R53-2-20240831","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00002826-199106000-00009","article-title":"Weight gain, increased appetite, and excessive food intake induced by carbamazepine","volume":"14","author":"Lampl","year":"1991","journal-title":"Clin Neuropharmacol"},{"key":"R54-2-20240831","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eplepsyres.2009.04.005","article-title":"The effect of carbamazepine treatment on serum leptin levels","volume":"86","author":"Uludag","year":"2009","journal-title":"Epilepsy Res"},{"key":"R55-2-20240831","doi-asserted-by":"crossref","first-page":"125S","DOI":"10.1111\/j.1365-2125.1989.tb03473.x","article-title":"Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy","volume":"27","author":"Remy","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"R56-2-20240831","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.1992.tb05079.x","article-title":"Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy","volume":"86","author":"Tartara","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"R57-2-20240831","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(98)10531-7","article-title":"Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: A multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group","volume":"354","author":"Chadwick","year":"1999","journal-title":"Lancet"},{"key":"R58-2-20240831","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/seiz.2000.0382","article-title":"Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group","volume":"9","author":"Guberman","year":"2000","journal-title":"Seizure"},{"key":"R59-2-20240831","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/WNL.51.5.1282","article-title":"A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77","volume":"51","author":"Chadwick","year":"1998","journal-title":"Neurology"},{"key":"R60-2-20240831","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1059-1311(98)90009-7","article-title":"Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: An open, observational study. The French Gabapentin Collaborative Group","volume":"7","author":"Baulac","year":"1998","journal-title":"Seizure"},{"key":"R61-2-20240831","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/00007691-199708000-00006","article-title":"Changes in body weight with chronic, high-dose gabapentin therapy","volume":"19","author":"DeToledo","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R62-2-20240831","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1212\/WNL.49.3.746","article-title":"Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82\/83","volume":"49","author":"Beydoun","year":"1997","journal-title":"Neurology"},{"key":"R63-2-20240831","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.seizure.2007.10.004","article-title":"Bodyweight gain under pregabalin therapy in epilepsy: Mitigation by counseling patients?","volume":"17","author":"Hoppe","year":"2008","journal-title":"Seizure"},{"key":"R64-2-20240831","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1212\/01.wnl.0000244422.45278.ff","article-title":"Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial","volume":"67","author":"Siddall","year":"2006","journal-title":"Neurology"},{"key":"R65-2-20240831","doi-asserted-by":"crossref","first-page":"v65","DOI":"10.1093\/ndt\/gft242","article-title":"Obesity as an effect modifier of the risk of death in chronic kidney disease","volume":"28","author":"Kramer","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R66-2-20240831","first-page":"323","article-title":"Neck circumference and central obesity are independent predictors of coronary artery disease in patients undergoing coronary angiography","volume":"2","author":"Zen","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"R67-2-20240831","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: Clinical impact, potential mechanisms, and new innovative treatment options","volume":"72","author":"L\u00f6scher","year":"2020","journal-title":"Pharmacol Rev"},{"key":"R68-2-20240831","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"R69-2-20240831","first-page":"817","article-title":"Anthropometric profile and nutritional intake in patients with epilepsy","volume":"32","author":"de Azevedo Fernandez","year":"2015","journal-title":"Nutr Hosp"},{"key":"R70-2-20240831","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1684\/epd.2014.0677","article-title":"Obesity and its association with generalised epilepsy, idiopathic syndrome, and family history of epilepsy","volume":"16","author":"Ladino","year":"2014","journal-title":"Epileptic Disord"},{"key":"R71-2-20240831","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.seizure.2021.07.019","article-title":"Associations of overweight and obesity with drug-resistant epilepsy","volume":"92","author":"Chen","year":"2021","journal-title":"Seizure"},{"key":"R72-2-20240831","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s11910-006-0027-6","article-title":"State of the ketogenic diet(s) in epilepsy","volume":"6","author":"Huffman","year":"2006","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R73-2-20240831","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.yebeh.2015.10.021","article-title":"A prospective study of the modified Atkins diet for adults with idiopathic generalized epilepsy","volume":"53","author":"Kverneland","year":"2015","journal-title":"Epilepsy Behav"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_139_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:13:01Z","timestamp":1787166781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_139_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_139_22","relation":{},"ISSN":["1596-3519"],"issn-type":[{"value":"1596-3519","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}